Protein array-based companion diagnostics in precision medicine. (1st December 2020)

• Record Type: Journal Article
• Authors: Poulsen, Thomas B. G.; Karamehmedovic, Azra; Aboo, Christopher; Jørgensen, Malene Møller; Yu, Xiaobo; Fang, Xiangdong; Blackburn, Jonathan M.; Nielsen, Claus H.; Kragstrup, Tue W.; Stensballe, Allan
• Is Part Of: Expert review of molecular diagnostics. Volume 20:Number 12(2020)
• Page Start: 1183
• Page End: 1198
• Publication Date: 2020-12-01
• Subjects: Autoimmune diseases -- companion diagnostics -- cdx -- oncology -- point-of-care -- precision medicine -- predictive biomarkers -- protein array; Molecular diagnosis -- Periodicals; 616.0758205
• DOI: 10.1080/14737159.2020.1857734
• Languages: English
• ISSNs: 1473-7159

Abstract

ABSTRACT: Introduction: The development of companion diagnostics (CDx) will increase efficacy and cost-benefit markedly, compared to the currently prevailing trial-and-error approach for treatment. Recent improvements in high-throughput protein technology have resulted in large amounts of predictive biomarkers that are potentially useful components of future CDx assays. Current high multiplex protein arrays are suitable for discovery-based approaches, while low-density and more simple arrays are suitable for use in point-of-care facilities. Area covered: This review discusses the technical platforms available for protein array focused CDx, explains the technical details of the platforms and provide examples of clinical use, ranging from multiplex arrays to low-density clinically applicable arrays. We thereafter highlight recent predictive biomarkers within different disease areas, such as oncology and autoimmune diseases. Lastly, we discuss some of the challenges connected to the implementation of CDx assays as point-of-care tests. Expert opinion: Recent advances in the field of protein arrays have enabled high-density arrays permitting large biomarker discovery studies, which are beneficial for future CDx assays. The density of protein arrays range from a single protein to proteome-wide arrays, allowing the discovery of protein signatures that may correlate with drug response. Protein arrays will undoubtedly play a key role in future CDx assays.